Mereo BioPharma Group (NASDAQ:MREO – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They presently have a $7.00 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 113.41% from the company’s current […]